Peter Thiel
Peter Thiel is the President of Clarium Capital Management, a hedge fund with $6 billion under mangement. Peter co-founded PayPal and served as its Chairman and CEO until the company's sale to eBay in October 2002 for $1.5 billion. Peter's experience in finance includes managing a successful hedge fund, trading derivatives at CS Financial Products, and practicing securities law at Sullivan & Cromwell. Peter sits on the Board of Directors of the Pacific Research Institute and on the Board of Visitors of Stanford Law School. Peter received his BA in Philosophy and his JD from Stanford.
View Older Stories View More Recent Stories
-
Peter Thiel Alum Rebrands Venture Capital Firm as Aloft VC
-
Explainer-ChatGPT: What is OpenAI’s chatbot and what is it used for?
-
Pylon Closes $8.5M Seed Round to Build the Embedded Mortgage Infrastructure Platform
-
Crypto lender BlockFi files for bankruptcy, cites FTX exposure
-
Democrat Mark Kelly holds seat in Arizona's U.S. Senate race
-
Factbox-Georgia U.S. Senate race going to runoff
-
Factbox-Democrat Fetterman wins U.S. Senate seat in Pennsylvania, Edison Research projects
-
Mastodon: What is the social network hailed as a Twitter alternative?
-
This Week in Transportation News: 7 Stories You Need to See
-
HD Hyundai CEO Chung Ki-sun Discussed Business Expansion with Chairman Peter Thiel of Palantir Technologies
-
Factbox-From outer space to social media, Elon Musk's growing universe
-
Techonomy 2022 Launches "Innovation Must Save the World" Conference
-
Peptilogics to Present Data at IDWeek 2022 on PLG0206, an Engineered Antimicrobial Peptide Targeting Bacteria Causing Periprosthetic Joint Infection
-
Mercantile Launches Industry-Specific Credit Card Platform That Supports Small Business Success
-
Peptilogics Presents Data Demonstrating Antimicrobial Activity Against Difficult to Treat Bacterial Pathogens of Engineered Peptide PLG0206 at the 2022 ASM/ESCMID Joint Conference on Drug Development
-
Peptilogics Announces First Patient Dosed in Phase 1b Study of PLG0206 for Periprosthetic Joint Infection
-
Outside dollars help Republican U.S. Senate candidates close financial gap with Democrats
-
Factbox-Eight U.S. Senate races to watch in November's midterm elections
-
Palantir signs $20 million deal with S.Korea's Hyundai Heavy Industries
-
Portofino Technologies Announces $50 Million Investment to Build Financial Infrastructure Technology to Power Digital Asset Adoption
-
QA Wolf Launches with over 20 Million Dollars to Bring Zero-Effort Automated QA to Developers at Scale
-
American voters deluged by ads in fight to control Congress, future elections
-
EpiAxis Therapeutics & Peptilogics Enter Strategic Drug Discovery Partnership
-
Movano Expands Go-To-Market Team with Vice President of UX and UI and Vice President of Digital Marketing and Growth
-
Peptilogics Strengthens Leadership Team with Executive Appointments
-
Palantir cuts revenue forecast, says govt contracts timing 'uncertain'
-
Proactive news headlines including Coinbase, Gold Resource, NEO Battery Materials, Empower Clinics, AMC Entertainment and Stuhini Exploration
-
Proactive news headlines including Coinbase, Gold Resource, NEO Battery Materials, Empower Clinics, AMC Entertainment and Stuhini Exploration
-
Two Republican women - a Trump critic and a devotee - await primary results
-
Trump-endorsed Masters wins Republican nomination for Arizona's U.S. Senate race
-
First-of-its-kind Dating App, Desti, Launches in Austin, Texas
-
Peptilogics to Participate in Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting in Pittsburgh
-
Factbox-Key races in Arizona, Michigan, Kansas, Missouri and Washington midterm primary elections
-
Trump-backed candidates prevail in U.S. midterm primaries; Kansas votes to preserve abortion rights
-
Factbox-The crypto crash hit these companies the hardest
-
Cleerly raises nearly $200 million in fundraise led by T. Rowe Price, Fidelity
-
Heart Health Innovator Cleerly Closes Series C Funding Round with $192 Million
-
Peptilogics Receives FDA Fast Track Designation for PLG0206, an Investigational Peptide Therapeutic in Development for the Treatment of Periprosthetic Joint Infection
-
Orion Biotechnology and Peptilogics Enter Strategic Research Collaboration to Enable AI-Driven Drug Discovery Against Undrugged GPCR Target
-
Orion Biotechnology and Peptilogics Enter Strategic Research Collaboration to Enable AI-Driven Drug Discovery Against Undrugged GPCR Target
-
Rubicon Technologies (FOUN) Appoints Jack Selby to its Post-Combination Board
-
Rubicon Announces Nomination of Jack Selby to its Post-Combination Board of Directors
-
Rubicon Announces Nomination of Jack Selby to its Post-Combination Board of Directors
-
Orion Biotechnology and Peptilogics Enter Strategic Research Collaboration to Enable AI-Driven Drug Discovery Against Undrugged GPCR Target
-
Mithril Capital’s Ajay Royan Sends Letter Thanking Adagio Therapeutics Shareholders for Support of Successful Proxy Campaign
-
Big Data Startup Zenysis Raises $13 Million Series B
-
Vauld, a leading crypto trading & lending platform's founders feature in Forbes Asia 30 under 30 list
-
Palantir, Trafigura aim to track carbon emissions for the oil industry
-
Palantir, Trafigura aim to track carbon emissions for the oil industry
-
Palantir, Trafigura aim to track carbon emissions for the oil industry

